SpringWorks Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• SpringWorks Therapeutics Inc SWTX.OQ reported a quarterly adjusted loss of $1.04​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.45. The mean expectation of seven analysts for the quarter was for a loss of 70 cents per share. Wall Street expected results to range from -73 cents to -65 cents per share.

• Revenue was $61.55 million​; analysts expected $59.12 million.

• SpringWorks Therapeutics Inc's reported EPS for the quarter was a loss of $1.04​.

• The company reported a quarterly loss of $77.3 million.

• SpringWorks Therapeutics Inc shares had risen by 54.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 8.9% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for SpringWorks Therapeutics Inc is $70.00

This summary was machine generated from LSEG data February 20 at 02:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)